According to real-time statistics released by Johns Hopkins University in the United States, as of 6:30 a.m. Beijing time on May 10, there were 4008497 confirmed cases of new coronary pneumonia worldwide, with a cumulative total of 278,135 deaths. Under the spread of the global new crown epidemic, many countries, including China, are “racing to the second” to develop a new corona pneumonia vaccine, some have entered the clinical trial stage. What’s the latest development in vaccine development? When can we use it?
At present, China has four new crown vaccines have been approved in clinical treatment, into the clinical trial stage. The four new crown vaccines are the adenovirus vector recombinant new coronavirus vaccine led by the team of Chen Wei academicians of the Academy of Military Sciences, the new coronavirus vaccine developed by Beijing Kexing Zhongwei Bio, and the two new crown inactivated vaccines approved clinically by China Bio of the National Pharmaceutical Group. China leads the world in the race to develop a new crown vaccine.
China: Four new crown vaccines in clinical trials
On May 6, Qin Chuan, a team from the Institute of Medical Experimental Animals of the Chinese Academy of Medical Sciences, led a team of researchers in the internationally renowned journal Science to publish the results of the world’s first new coronary vaccine animal trials, which confirmed that the new coronary inactivated vaccine developed by Zhongwei Bioinis in Beijing was safe and effective in the rhesus monkey model, the first publicly reported results of the new coronary vaccine animal experiment. Phase I/II clinical study was launched on April 16 in Yanning County, Xuzhou City, Jiangsu Province.
On April 12, the innovative recombinant vaccine product recombinant neo-coronavirus (adenovirus vector) vaccine, led by a team of Chen Wei academicians of the Chinese Academy of Military Sciences, officially began testing the trials in Wuhan, meaning that the world’s first new coronavirus vaccine entered Phase II clinical trials. About 500 volunteers were vaccinated, including an 84-year-old man who participated in a phase II clinical trial of the new coronary vaccine. In an interview, Mr. Chen said that if all goes well, May is expected to be blinded.
The two new crown inactivated vaccines approved for clinical use by China Pharmaceutical Group China are the first clinical trial approval, the new crown inactivated vaccine, which was approved by the China Biological Wuhan Biological Products Research Institute of China and the Wuhan Virus Research Institute of the Chinese Academy of Sciences, and the new crown inactivated vaccine jointly developed by the China Biological Beijing Biological Products Research Institute of China and the Virus Disease Prevention and Control Institute of the Chinese Center for Disease Control and Prevention, which launched phase I/II clinical trials on April 28.
When can I use the new coronavaccine? Gao Fu, director of the China Center for Disease Control and Prevention, said in an April 23 interview with China International Television that China is at the forefront of research and development of the new crown vaccine, which may be put into emergency use in September.
U.S.: Three new crown vaccines have been clinically tested
On May 5, local time, Pfizer announced on its official website that the new coronapneumonia program developed jointly by Pfizer and BioNTech, a German biotech company, has completed a Phase I/II clinical trial in the United States. The project is part of the NEW Coronary Pneumonia BNT162 vaccine program, and the first batch of drug delivery in Germany was completed last week.
The Phase I/II clinical trial is designed to simultaneously assess the safety, immunogenicity and optimal antibody levels of the four mRNA candidate vaccines in order to determine the safest and most effective vaccines, the statement said.
Meanwhile, on May 7, U.S. biotech company Moderna announced that its new crown vaccine has been approved by the FDA to enter phase II trial phase.
In addition, Inovio’s new coronary pneumonia DNA vaccine has been recruited by subjects, with a total of 40 healthy volunteers receiving the first dose of the vaccine and are currently in the process of verifying their safety, dosage and other relevant data.
UK: First clinical trial signed
The first milliondoses of vaccines at the Jenner Institute at Oxford University could go on sale in September, researchers at oxford University said in a clinical trial next month that will prove their effectiveness and get urgent approval from regulators.
The move follows the first human trials of the new coronavirus vaccine program at Oxford University on April 23.
Australia: Upcoming clinical trials
The new crown vaccine developed in Australia has produced good results in animal trials and, if the next human trial goes well, is expected to be mass-produced in September and widely available as early as the first half of 2021, the Daily Mail reported on April 30.
On May 8, local time, Mustafa Varanque, Turkey’s Minister of Industry and Science and Technology, said that three universities in Turkey are working on a new coronavirus vaccine, which is now in the animal experimental phase and is expected to be clinically tested by the end of the year.
France: not yet in the test phase
On April 14th The website of French drugmaker Sanofi announced that Sanofi and British drugmaker GlaxoSmithKline would work together to develop a new coronavirus vaccine. Clinical trials are expected to begin in the second half of 2020 and, if going well, will be available in the second half of 2021.